# Combined Immunotherapies in Metastatic ER+ Breast Cancer

> **NCT04563507** · PHASE2 · RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 102 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
- **DRUG:** Letrozole 2.5Mg Tab
- **DRUG:** Palbociclib 125mg

## Key facts

- **NCT ID:** NCT04563507
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-12
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04563507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04563507, "Combined Immunotherapies in Metastatic ER+ Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04563507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*